



CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all health benefit plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

Subject Interspinous Process Spacer Devices (e.g., X-STOP®)

Effective Date 4/15/2011
Next Review Date 4/15/2012
Coverage Policy Number 0448

Table of Contents

Coverage Policy	1
General Background	1
Coding/Billing Information	5
References	5
Policy History	8

Hyperlink to Related Coverage Policies

- Lumbar Fusion for Spinal Instability and Degenerative Disc Conditions
- Mechanical Devices for the Treatment of Back Pain
- Minimally Invasive Treatment of Back Pain

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2011 CIGNA

Coverage Policy

CIGNA does not cover interspinous process spacer devices (e.g., X-STOP®) for any indication because they are considered experimental, investigational or unproven

General Background

An interspinous process spacer device is an implant designed to preserve motion and provide symptomatic relief of pain associated with degenerative disc disease or spinal stenosis, with or without degenerative spondylolisthesis. Spinal stenosis is a narrowing of the vertebral canal that may lead to compression of the spinal nerves or nerve roots, especially in the lumbar vertebrae. Lumbar stenosis is commonly seen in an aging or degenerative spine. Bony overgrowth and ligament enlargement into the spinal canal, intervertebral disc herniation, or vertebral slippage (i.e., spondylolisthesis) may cause nerve compression resulting in low back pain, leg fatigue and pain, and reduced capacity for physical activity. Neurogenic claudication is a combination of low back and leg pain, with numbness and motor weakness when standing or walking that is relieved by sitting or lying. Treatment for back pain may include pharmacological therapy (e.g., non steroidal anti-inflammatory drugs (NSAIDs), analgesics, muscle relaxants), exercise, spinal manipulation, acupuncture, cognitive-behavioral therapy, and physical therapy. Various interventional and surgical procedures may be considered if these measures are unsuccessful. Surgical options include decompressive procedures (e.g., laminectomy) alone, or decompression and fusion. Fusion is frequently performed with rigid implant fixation systems, including pedicle screws and interbody cages. The use of interspinous process spacer devices has

been proposed as a less invasive dynamic stabilization alternative (Chou et al., 2009; Kim, 2007; Snyder, et al., 2004; Sengupta and Herkowitz, 2003).

U.S. Food and Drug Administration (FDA)

X-STOP® Interspinous Process Decompression (IPD) System (St. Francis Medical Technologies, Inc., Alameda, CA): The X-STOP system received FDA approval through the premarket approval (PMA) process on November 21, 2005. St. Francis Medical Technologies was subsequently acquired by Kyphon, Inc. (Sunnyvale, CA), and Kyphon was acquired by Medtronic, Inc., (Minneapolis, MN), in November, 2007.

The X-STOP System is a titanium implant with two components: a spacer assembly consisting of a tissue expander, an oval spacer and a fixed wing; and a wing assembly consisting of an adjustable wing and locking screw. The X-STOP procedure is performed under general or local anesthesia. A midline incision is made over the appropriate spinal level to display the spinous processes and their interspinous ligaments. The X-STOP device is positioned in the space between the flexed spinous processes to act as a physical block in order to prevent extension at the stenotic level and increase the dimensions of the spinal canal and intervertebral foramina. The procedure is designed to prevent extension when standing or walking, relieving pressure on the nerves.

According to the FDA approval order, the device is indicated for treatment of patients aged 50 or older with neurogenic intermittent claudication (NIC) secondary to a confirmed diagnosis of lumbar spinal stenosis, with x-ray, magnetic resonance imaging (MRI), and/or computed tomography (CT) evidence of thickened ligamentum flavum, narrowed lateral recess, and/or central canal narrowing. It is indicated for patients with moderately impaired physical function who experience relief in flexion from symptoms of leg/buttock/groin pain, with or without back pain, and who have undergone at least six months of nonoperative treatment. The approval order states that the X-STOP may be implanted at one or two lumbar levels in patients for whom operative treatment is indicated at no more than two levels.

Additional Devices: Several interspinous process spacer devices are currently under evaluation in clinical trials but have not received FDA approval, including the following:

- Wallis® Dynamic Posterior Stabilization System (Zimmer, Inc., Minneapolis, MN)
- Diam™ Spinal Stabilization System (Medtronic LLC, Minneapolis, MN)
- Coflex™ Interspinous Implant (Paradigm Spine, New York, NY).

Posterior non-pedicle supplemental fixation devices (e.g., Lanx Spinal Fixation System™ [Lanx, Inc., Broomfield CO], Aspen™ Spinous Process System [Lanx, Inc., Broomfield CO]) have been explored as a method of temporary spinal fixation while waiting for bony fusion to occur, as an alternative to pedicle screws. These devices differ from interspinous process spacer devices (e.g., X-STOP) in that they are used for fixation rather than for motion preservation. Although FDA approved, the safety and efficacy of these devices has not been established in the published medical literature. Refer to the Coverage Policy, Lumbar Fusion for Spinal Instability and Degenerative Disc Conditions for information on these devices.

Literature Review

A case series by Kuchta et al. (2008) evaluated two-year results of X-STOP implantation in 175 patients with neurogenic intermittent claudication due to lumbar spinal stenosis. Patients were evaluated using the VAS score and Oswestry disability index. The average preoperative VAS score was 61.1 (range, 20–100) and decreased to an average of 39.0 (range 0–100) at six weeks ($p < 0.005$). Mean VAS at 6, 12, and 24 months was 35.8 (range 0–100); 38.6 (range 0–100); and 39.0 (range 0–75), respectively. The average preoperative ODI score was 32.6 (range 8–80) and decreased to an average of 22.7 at six weeks (range 0–85). The average ODI score at 6, 12, and 24 months was 21.5 (range 0–66); 15.3 (range 0–44); and 20.3 (range 0–42), respectively. Removal of the device was required in 8 of 175 patients because of unsatisfactory effect, and a microsurgical decompression was performed.

Verhoof et al. (2007) reported outcomes of X-STOP implantation in 12 consecutive patients with symptomatic lumbar stenosis caused by degenerative spondylolisthesis. The authors noted that only one other study had investigated the clinical effects of the X-STOP in patients whose spinal stenosis was caused by spondylolisthesis. All patients had low back pain, neurogenic claudication and radiculopathy. The mean follow-up was 30.3 months. Complete relief of symptoms was observed in eight patients immediately following the

procedure, and four patients experienced no improvement. At 12 weeks, two patients who initially had experienced symptom relief experienced a recurrence of pain, neurogenic claudication, and radiculopathy, and at 24 months, a third patient experienced a recurrence of symptoms. The implant was removed in the seven patients with persistent or recurrent symptoms, and decompression and posterolateral fusion with instrumentation was performed. The authors stated that, because of the high failure rate, they do not recommend the X-STOP for the treatment of spinal stenosis complicating degenerative spondylolisthesis, and that spondylolisthesis should be considered a contraindication for the X-STOP device.

Siddiqui et al. (2007) conducted a small retrospective study to evaluate the clinical outcome of patients with symptomatic lumbar spinal stenosis treated with X-STOP implantation, and to compare this data with previous studies. Forty consecutive patients were enrolled between January 2003 and December 2006. Two patients were excluded from the study because conversion to surgical decompression was required due to intraoperative fracture of spinous processes during the X-STOP procedure. One patient was declared unfit for surgery due to medical comorbidities and was also excluded. Patients were evaluated preoperatively and at three months, six months and one year, using with the Zurich Claudication Questionnaire (ZCQ), ODI, and Standard Form (SF)-36. Only 24 of 37 patients completed the full set of questionnaires. At a mean follow-up of 12 months, mean ODI scores had improved from 48 to 37, mean ZCQ Symptom Severity scores improved from 3.4 to 2.8, and mean ZCQ Physical Function scores improved from 2.5 to 2.2. Improvements were observed in five of the ten SF-36 sub-scores. The published study does not state whether any of the improvements noted were statistically significant, however. The X-STOP was removed in two patients who were noted to have dorsally slipped implants at one year, with symptoms of neurogenic claudication. Both patients were treated with decompression and fusion.

Zucherman et al. (2005) conducted a randomized controlled multicenter trial to determine the safety and efficacy of the X-STOP in patients with NIC secondary to lumbar spinal stenosis. FDA approval was based primarily on the results of this trial. Patients with spondylolisthesis of greater than grade one on a one to four scale were excluded from participation. Patients were randomized to treatment with the X-STOP (n=100) or nonoperative therapies (n=91). Patients randomized to the control group received at least one epidural steroid injection following enrollment and were prescribed additional epidural steroid injections, nonsteroidal anti-inflammatory medications, analgesics and physical therapy as needed. The primary outcome measure was the Zurich Claudication Questionnaire (ZCQ), a patient-completed validated instrument to evaluate NIC. Assessments were made prior to treatment and at six weeks, six months, one year and two years, and were based on ZCQ symptom severity and physical function domains and the patient satisfaction domain. Seven patients in the X-STOP group and 10 patients in the control group were lost to follow-up. At each follow-up, patients in the X-STOP group had significantly better outcomes in each domain of the ZCQ. At two years, the X-STOP patients improved by 45.4% over the mean baseline symptom severity score, compared to 7.4% in the control group. The mean improvement in the physical function domain was 44.3% in the X-STOP group and -0.4% in the control group, and 73.1% of patients in the X-STOP group were satisfied with their treatment compared to 35.9% of the control group. The authors concluded that the X-STOP provides a conservative yet effective treatment for patients suffering from lumbar spinal stenosis. Although this study demonstrated positive results, it is difficult to generalize these findings, since the study included a highly selected patient population; those with spondylolisthesis higher than grade one on a scale of one to four were excluded from the study. In addition, the follow-up period was relatively short, and a significant number of patients were lost to follow-up and were not included in the analysis.

Kondrashov et al. (2006) conducted a small case series to evaluate the X-STOP in 18 patients. Inclusion criteria were based on the FDA PMA approval criteria. Twelve patients had the X-STOP implanted at either L3-4 or L4-5 levels, and six patients had the device implanted at both L3-4 and L4-5 levels. The mean preoperative Oswestry Disability Index (ODI) score was 45 (range 20-80). At an average follow-up of 51 months (range 45-61 months), the mean ODI score was 15 (range 0-36). Using a 15-point improvement from baseline as the criterion for success, the authors reported that 14 of 18 patients had a successful outcome. It is difficult to draw conclusions from this study because of the small number of patients studied, limited follow-up, and the lack of a control group treated with nonsurgical or traditional surgical approaches.

Lee et al. (2004) conducted a small case series (n=10) to evaluate the safety and efficacy of the X-STOP in elderly patients with lumbar spinal stenosis. Patients were assessed postoperatively by MRI and the Swiss Spinal Stenosis (SSS) Questionnaire. There were no complications reported. At a minimum follow-up of nine months, the patient satisfaction domain of the SSS Questionnaire demonstrated that 70% of the patients were at

least somewhat satisfied with the outcome of the surgery. The cross-sectional area of the dural sac increased postoperatively by 22.3%, and the intervertebral foramina increased by 36.5%. Only one patient showed a significant improvement in physical functioning. The authors concluded that this minimally invasive procedure provides a new treatment for elderly patients with lumbar spinal stenosis.

In a review of dynamic interspinous process technology, Christie et al. (2005) discuss several available spinal implants, including the X-STOP, Wallis and Diam devices. The authors state that, although outcomes of patients treated with the X-STOP have been reported as comparable to outcomes of patients treated with laminectomy, a direct comparison between these two methods in a controlled clinical trial has yet to be reported. The concept of dynamic stabilization is an attractive alternative to fusion, especially in younger patients who would bear a greater burden on adjacent segments during their prolonged follow-up. In addition, the procedure does not limit potential therapeutic options. The authors stated that, although early results of experimental use of interspinous implants are promising, no meaningful comparison can be made between any of these implants at this time, nor can a comparison be made between implants and traditional surgical approaches such as laminectomy and/or fusion.

Kim and Albert discuss concerns and controversy regarding this technology in a review of interspinous process spacers, including the X-STOP, Wallis, and Diam devices. The authors state that interspinous spacer implants are designed to produce increased segmental kyphosis (spinal process flexion) at the treated level, and concern has been raised about the potentially harmful effect of local kyphosis on adjacent segments. There are no long-clinical data regarding the effects of increased kyphosis resulting from placement of interspinous process spacers. The authors also state that, because the spinous process normally serves as an origin and insertion site for muscles and ligaments, and does not normally act as a compressive load bearing structure, it is possible that compression loading of the spinous processes and cyclic device motion may lead to local tissue changes and pain generation. Another concern raised by the authors is the lack of evidence of the impact of interspinous implants on the intricate system of reflex arcs that have been hypothesized to be responsible for maintaining segmental stability during motion and positioning of the spine. In addition, the lumbar functional spinal unit demonstrates viscoelasticity under conditions of constant compression and tension, yet this phenomenon is not accounted for in current device insertion techniques. The X-STOP device involves fairly rapid sizing of the interspinous space with a dilator to select the appropriately sized implant. Progressive subsidence over time was also mentioned as a concern.

National Institute for Health and Clinical Excellence (NICE) (United Kingdom)

Interventional Procedures Guidance for interspinous distraction procedures for lumbar spinal stenosis causing neurogenic claudication was originally issued by NICE in 2006, and updated on November, 2010. The revised guidance states that current evidence shows that these procedures are efficacious for carefully selected patients in the short and medium term, although failure may occur and further surgery may be needed. The guidance states that there are no major safety concerns, and that these procedures may be used provided that normal arrangements are in place for clinical governance, consent and audit. The guidance also states that patient selection should be carried out by specialist spinal surgeons who are able to offer patients a range of surgical treatment options.

Professional Societies/Organizations

The North American Spine Society (NASS) evidence-based clinical guideline on the diagnosis and treatment of degenerative lumbar spondylolisthesis (Watters et al., 2009) includes an evaluation of interventional and surgical treatments, including interspinous spacers. The guideline states that there is insufficient evidence to recommend indirect surgical decompression for treatment of patients with symptomatic spinal stenosis associated with low grade degenerative lumbar spondylolisthesis whose symptoms have been recalcitrant to a trial of medical/interventional treatment. This conclusion is consistent with earlier recommendations included in the NASS 2007 clinical guideline on the diagnosis and treatment of degenerative lumbar spinal stenosis

The authors note that independent randomized controlled trials are needed to validate what appears to be an effective and minimally invasive means (interspinous spacers) of decompressing the spinal canal in patients with symptomatic spinal stenosis and degenerative lumbar spondylolisthesis.

Summary

The use of various interspinous process spacer devices has been proposed as a minimally invasive alternative for treatment of pain associated with degenerative disc disease and spinal stenosis. Early results of the X-

STOP® Interspinous Process Decompression (IPD) System are promising, but there is insufficient evidence to demonstrate the long-term safety, efficacy, and durability of the device. Several additional devices, including the Wallis® Dynamic Posterior Stabilization System; the Diam™ Spinal Stabilization System, and the Coflex™ Interspinous Implant, are being evaluated in clinical trials but have not received U.S. Food and Drug Administration (FDA) approval. There is insufficient evidence in the published medical literature to demonstrate the safety, efficacy, and long-term outcome interspinous process spacer devices, or to determine how the use of these devices compares to alternative medical, interventional, or surgical treatment.

Coding/Billing Information

Note: This list of codes may not be all-inclusive.

Experimental/Investigational/Unproven/Not Covered:

CPT* Codes	Description
0171T	Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level
0172T	Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level (List separately in addition to code for primary procedure)

HCPCS Codes	Description
C1821	Interspinous process distraction device (implantable)

ICD-9-CM Diagnosis Codes	Description
724.02	Spinal stenosis, other than cervical, lumbar region
	All other codes

*Current Procedural Terminology (CPT®) © 2010 American Medical Association: Chicago, IL.

References

1. Anderson PA, Tribus CB, Kitchel SH. Treatment of neurogenic claudication by interspinous decompression: application of the X-STOP device in patients with lumbar degenerative spondylolisthesis. *J Neurosurg Spine*. 2006 Jun;4(6):463-71.
2. Asgarzadie F, Khoo LT. Minimally invasive operative management for lumbar spinal stenosis: overview of early and long-term outcomes. *Orthop Clin North Am*. 2007 Jul;38(3):387-99; abstract vi-vii.
3. AzzazziA, Elhawary Y. Dynamic Stabilization Using X-stop Versus Transpedicular Screw Fixation in the Treatment of Lumbar Canal Stenosis; Comparative Study of the Clinical Outcome. *Neurosurg Q*; 2010 Sept;20(3):165-169.
4. Canale and Beaty: *Campbell's Operative Orthopaedics*, 11th ed. Mosby, an imprint of Elsevier; 2007.
5. Christie SD, Song JK, Fessler RG. Dynamic interspinous process technology. *Spine*. 2005 Aug 15;30(16 Suppl):S73-8.

6. ECRI Institute. Hotline Response [database online]. Plymouth Meeting (PA): ECRI Institute; 2009 Oct 7. Interspinous Process Decompression to Treat Spinal Stenosis. Available at URL address: <http://www.ecri.org>
7. ECRI Institute. Interspinous process decompression to treat spinal stenosis. [Emerging Technology evidence report]. Plymouth Meeting (PA): ECRI Institute; 2009 Mar 9. Available at URL address: <http://www.ecri.org>
8. Gibson JNA, Waddell G. Surgery for degenerative lumbar spondylosis: updated Cochrane Review. *Spine*. 2005 Oct 15;30(20):2312-20.
9. Gunzburg R, Szpalski M. The conservative surgical treatment of lumbar spinal stenosis in the elderly. *Eur Spine J*. 2003 Oct;12 Suppl 2:S176-80. Epub 2003 Sep 5.
10. Hayes brief. X-Stop® Interspinous Process Decompression System (Kyphon, Inc.) for Lumbar Spinal Stenosis. Lansdale, PA: Hayes Inc; ©2007 Winifred S. Hayes, Inc. 2007 Nov 13.
11. Hsu KY, Zucherman JF, Hartjen CA, Mehalic TF, Implicito DA, Martin MJ, et al. Quality of life of lumbar stenosis-treated patients in whom the X-STOP interspinous device was implanted. *J Neurosurg Spine*. 2006 Dec;5(6):500-7.
12. Isaac Z, Katz JN, Mody E. Lumbar spinal stenosis. In: *Arthritis and allied conditions*. Philadelphia: Lippincott, Williams & Wilkins; 2005.
13. Kabir SMR, Gupta SR, Casey ATH. Lumbar interspinous spacers: a systematic review of clinical and biomechanical evidence. *Spine (Phila Pa 1976)*. 2010 Dec 1;35(25):E1499-506.
14. Katz Jn, Harris MB. Clinical practice. Lumbar spinal stenosis. *N Engl J Med*. 2008 Feb 21;358(8):818-25.
15. Khoeir P, Kim KA, Wang MY. Classification of posterior dynamic stabilization devices. *Neurosurg Focus*. 2007 Jan 15;22(1):E3.
16. Kim DH, Albert TJ. Interspinous process spacers. *J Am Acad Orthop Surg*. 2007 Apr;15(4):200-7.
17. Kondrashov DG, Hannibal M, Hsu KY, Zucherman JF. Interspinous process decompression with the X-STOP device for lumbar spinal stenosis: a 4-year follow-up study. *J Spinal Disord Tech*. 2006 Jul;19(5):323-7.
18. Kuchta J, Sobottke R, Eysel P, Simons P. Two-year results of interspinous spacer (X-Stop) implantation in 175 patients with neurologic intermittent claudication due to lumbar spinal stenosis. *Eur Spine J*. 2009 Jun;18(6):823-9. Epub 2009 Apr 22.
19. Lee J, Hida K, Seki T, Iwasaki Y, Minoru A. An interspinous process distractor (X-STOP) for lumbar spinal stenosis in elderly patients: preliminary experiences in 10 consecutive cases. *J Spinal Disord Tech*. 2004 Feb;17(1):72-7; discussion 78.
20. National Institute for Health and Clinical Excellence (NICE). Interventional procedure guidance 165. Interspinous distraction procedures for lumbar spinal stenosis. London, UK: NICE; 2010 Nov. Accessed Mar 13, 2011. Available at URL address: <http://guidance.nice.org.uk/IPG365>
21. Sengupta DK. Dynamic stabilization devices in the treatment of low back pain. *Orthop Clin North Am*. 2004 Jan;35(1):43-56.
22. Sengupta DK., Herkowitz HN. Lumbar spinal stenosis. Treatment strategies and indications for surgery. *Orthop Clin North Am*. 2003 Apr;34(2):281-95.

23. Siddiqui M, Nicol M, Karadimas E, Smith F, Wardlaw D. The positional magnetic resonance imaging changes in the lumbar spine following insertion of a novel interspinous process distraction device. *Spine*. 2005 Dec 1;30(23):2677-82.
24. Siddiqui M, Smith FW, Wardlaw D. One-year results of X-Stop interspinous implant for the treatment of lumbar spinal stenosis. *Spine*. 2007 May 20;32(12):1345-8.
25. Snyder DL, Doggett D, Turkelson C. Treatment of degenerative lumbar spinal stenosis. *Am Fam Physician*. 2004 Aug 1;70(3):517-20.
26. Sobottke R, Schlüter-Brust K, Kaulhausen T, Röllinghoff M, Joswig B, Stützer H, et al. Interspinous implants (X Stop, Wallis, Diam) for the treatment of LSS: is there a correlation between radiological parameters and clinical outcome? *Eur Spine J*. 2009 Oct;18(10):1494-503. Epub 2009 Jun 27
27. Talwar V, Lindsey DP, Fredrick A, Hsu KY, Zucherman JF, Yerby SA. Insertion loads of the X-STOP interspinous process distraction system designed to treat neurogenic intermittent claudication. *Eur Spine J*. 2005 May 31; [Epub ahead of print].
28. U. S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Premarket approval database. New Device Approval: X-Stop® Interspinous Process Decompression System. P040001. Accessed Mar 21, 2010. Available at URL address: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm>
29. Verhoof OJ, Bron JL, Wapstra FH, van Royen BJ. High failure rate of the interspinous distraction device (X-Stop) for the treatment of lumbar spinal stenosis caused by degenerative spondylolisthesis. *Eur Spine J*. 2008 Feb;17(2):188-92. Epub 2007 Sep 11.
30. Watters WC 3rd, Bono CM, Gilbert TJ, Kreiner DS, Mazanec DJ, Shaffer WO, Baisden J et al. North American Spine Society. An evidence-based clinical guideline for the diagnosis and treatment of degenerative lumbar spondylolisthesis. *Spine J*. 2009 Jul;9(7):609-14. Epub 2009 May 17. Accessed Mar 13, 2011. Available at URL address: http://www.spine.org/Documents/Spondylolisthesis_Clinical_Guideline.pdf
31. Watters WC, Baisden J, Gilbert T, Kreiner DS, Resnick D, Bono C, et al. Degenerative lumbar spinal stenosis: an evidence-based clinical guideline for the diagnosis and treatment of degenerative lumbar spinal stenosis. *Spine J*. 2008 Mar-Apr;8(2):305-10. Epub 2007 Dec 21. Accessed Mar 13, 2011. Available at URL address: http://www.spine.org/Documents/NASSCG_Stenosis.pdf
32. Weinstein Jn, Tosteson TD, Lurie JD, Tosteson ANA, Blood E, Hanscom B, et al. for the SPORT Investigators. Surgical versus nonsurgical therapy for lumbar spinal stenosis. *N Engl J Med*. 2008 Feb 21;358(8):794-810.
33. Yi X, McPherson B. Application of X STOP device in the treatment of lumbar spinal stenosis. *Pain Physician*. 2010 Sep-Oct;13(5):E327-36
34. Zucherman JR, Hsu KY, Hartjen CA, Mehalic TF, Implicito DA, Martin MJ, et al. A multicenter, prospective, randomized trial evaluating the X-STOP interspinous process decompression system for the treatment of neurogenic intermittent claudication: two-year follow-up results. *Spine*. 2005 Jun 15;30(12):1351-8.
35. Zucherman JR, Hsu KY, Hartjen CA, Mehalic TF, Implicito DA, Martin MJ, et al. A prospective randomized multi-center study for the treatment of lumbar spinal stenosis with the X-STOP interspinous implant: 1-year results. *Eur Spine J*. 2004 Feb;13(1):22-31. Epub 2003 Dec 19.

Policy History

Pre-Merger Organizations	Last Review Date	Policy Number	Title
CIGNA HealthCare	4/15/2008	0448	Interspinous Process Decompression Devices (e.g., X-STOP)
Great-West Healthcare	12/20/2007	05.320.02	X Stop Interspinous Process Decompression System for Lumbar Stenosis

“CIGNA”, “CIGNA HealthCare” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Health and Life Insurance Company, CIGNA Behavioral Health, Inc., CIGNA Health Management, Inc., and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company or CIGNA Health and Life Insurance Company.